Theravance and Janssen to Advance TD-1473 for Treatment of Inflammatory Bowel Diseases

Theravance and Janssen to Advance TD-1473 for Treatment of Inflammatory Bowel Diseases
Theravance Biopharma Ireland Limited, a Theravance Biopharma subsidiary, and Janssen Biotech have joined forces to develop and commercialize the investigational therapy TD-1473 as a treatment for inflammatory bowel diseases (IBDs) such as Crohn’s disease and ulcerative colitis. TD-1473 is an orally administered, highly specific inhibitor of the Janus kinase (JAK) family of enzymes, which play a critical role in inflammation. JAK inhibitors are currently approved to treat rheumatoid arthritis (RA) and myelofibrosis. They have also demonstrated some benefit for patients with ulcerative colitis. However, these products are known to have certain side effects associated with their systemic exposure. TD-1473 has a specific type of activity that is restricted to the intestinal tract, which prevents the risk of systemic exposure and unwanted side effects. Under the agreement, Theravance will receive $100 million upfront from Janssen, one the Janssen Pharmaceutical Companies of Johnson & Johnson. And Theravance will be eligible to receive an additional $900 million if Janssen chooses to remain in the collaboration after certain milestones are met. "Internally, we have been very excited about the potential of TD-1473 to serve as a transformational medicine designed to offer the proven therapeutic activity of JAK inhibitors without the safety concerns associated with systemic JAK exposure. We believe this transaction can accelerate the development of TD-1473 and maximize the potential value of the program to Theravance Biopharma," Rick E. Winningham, chairman and chief executive officer of the Theravance Biopharma Group, said in a press release. Theravance is also planning to initiate a Phase 2b/3 adaptive design induction and maintenance study in ulcera
Subscribe or to access all post and page content.